FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Zacks11-20

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate FT819. Data ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484903430?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d","is_english":true,"pubTime":"2024-11-20 02:55","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484903430","market":"us","top_or_hot":-1,"title":"FATE Presents Encourgaing Data From Lupus Study, Stock Gains","media":"Zacks","content":"<div>\n<p>Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.\nData ...</p>\n\n<a href=\"https://finance.yahoo.com/news/fate-presents-encourgaing-data-lupus-185500828.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FATE Presents Encourgaing Data From Lupus Study, Stock Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFATE Presents Encourgaing Data From Lupus Study, Stock Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 02:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/fate-presents-encourgaing-data-lupus-185500828.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.\nData ...</p>\n\n<a href=\"https://finance.yahoo.com/news/fate-presents-encourgaing-data-lupus-185500828.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLE","symbol_name":"Super League Gaming Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/fate-presents-encourgaing-data-lupus-185500828.html","article_id":"2484903430","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484903430","pubTimestamp":1732042500,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate FT819.Data showed that the first patient suffering from active lupus nephritis  and treated with FT819 had favorable clinical experience, achieved drug-free clinical remission and continued on-study free of all immunosuppressive therapy.Shares of Fate have lost 42.8% year to date compared with the industry’s decline of 11.1%.FT819 is FATE’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.The initial results are promising, and FATE believes this differentiated therapeutic approach has the potential to transform outcomes for patients with autoimmune diseases without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy and extended hospital","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLE":"Super League Gaming Inc.","SPRO":"Spero Therapeutics Inc.","BK4505":"高瓴资本持仓","FATE":"Fate Therapeutics Inc","BK4077":"互动媒体与服务","BK4139":"生物科技","CSTL":"Castle Biosciences, Inc.","IMCR":"Immunocore Holdings plc","BK4196":"保健护理服务"},"translate_title":"FATE呈现狼疮研究令人鼓舞的数据，股票上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":1,"FATE":1,"IMCR":1,"SLE":1,"SPRO":0.9},"content_text":"Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.\nData showed that the first patient suffering from active lupus nephritis (LN) and treated with FT819 had favorable clinical experience, achieved drug-free clinical remission and continued on-study free of all immunosuppressive therapy.\nShares gained 12.38% on the news data.\nShares of Fate have lost 42.8% year to date compared with the industry’s decline of 11.1%.\nImage Source: Zacks Investment Research\nFATE’s Six-Month Follow-up Data on FT819\nFT819 is FATE’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.\nThe ongoing multi-center phase I  study for patients with moderate-to-severe systemic lupus erythematosus (SLE) is designed to evaluate the safety, pharmacokinetics and anti-B cell activity of FT819 (NCT06308978).\nThe first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells.\nAmong these, a 27-year-old African American-Asian woman diagnosed with LN over ten years ago achieved DORIS (definition of remission in SLE) clinical remission and LLDAS (low lupus disease activity state) at follow-up after six months. The patient also experienced a resolution of fatigue, something that rheumatologists struggle to improve with other treatments.\nThis woman continues to be on study, in clinical remission, and free of all immunosuppressive therapies as of a data cutoff date of Nov. 11, 2024.\nAs of the same date, the patient did not experience any serious event or events of any grade of cytokine release syndrome, immune effector-cell associated neurotoxicity syndrome, or graft-versus-host disease.\nThe initial results are promising, and FATE believes this differentiated therapeutic approach has the potential to transform outcomes for patients with autoimmune diseases without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy and extended hospitalization.\nFATE is also enrolling a second treatment arm under the FT819 phase I autoimmunity study to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. This new arm is being conducted with the study’s conditioning arm.\nFATE’s Promising Pipeline\nFATE is focused on developing and manufacturing universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell product platform. Its immuno-oncology pipeline includes iPSC-derived natural killer cells and T-cell product candidates.\nFate is co-developing FT825/ONO-8250, a multiplexed-engineered, iPSC-derived CAR T-cell product candidate, with ONO Pharmaceutical. The company is conducting a multi-center, phase I study to assess the safety, pharmacokinetics and activity of FT825/ONO-8250 in patients with advanced solid tumors.\nA phase I study of FT522 in patients with relapsed/refractory B-cell lymphoma is ongoing.\nZacks Rank & Stocks to Consider\nFATE currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR,  Spero Therapeutics SPRO and Castle Biosciences, Inc. CSTL, each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time frame. Year to date, shares of IMCR have lost 54.6%.\nIMCR’s earnings beat estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 25.57%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.31. Estimates for 2025 loss per share have narrowed from $1.54 to $1.16. Year to date, shares of Spero Therapeutics have lost 20.4%.\nSpero Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 94.42%.\nIn the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time frame. Year to date, shares of CSTL have surged 29.3%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nFate Therapeutics, Inc. (FATE) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nImmunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484903430"}